Scalper1 News
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) reported good late-stage trial data for its new HIV drug Wednesday. Analysts nicknamed the drug “son of Viread” and expect it to be a blockbuster. The stock was up about 2.2% by afternoon trading on the stock market today. The two trials compared a standard combination of four drugs that are combined in Gilead’s (GILD) most advanced marketed product, Stribild, to one in which one of the Scalper1 News
Scalper1 News